Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & ProteinsLa Merie Publishing released on March 9, 2018 the 12th edition of reports about sales of Blockbuster Biologics. This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2017. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 18 2017. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).
A total of 45 biologic therapeutics reached blockbuster status with 2017 sales exceeding US$ 1 bln: 27 antibodies and 18 proteins. Fourteen new biologics with sales data were included fort he first time in this compilation. Ten biologics reached global sales in 2017 of more than US$ 5 bln. Three biologics were new in the blockbuster biologics list. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2017 sales higher than US$ 1 bln. Another ranking list was prepared for TOP 30 companies according to biologics sales in 2017 and the percentage of antibody sales of total biologics sales.